Entrada Therapeutics, Inc.
$13.56
▼
-2.45%
2026-04-21 09:53:01
www.entradatx.com
NGM: TRDA
Explore Entrada Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$535.6 M
Current Price
$13.56
52W High / Low
$14.49 / $4.93
Stock P/E
—
Book Value
$8.5
Dividend Yield
—
ROCE
-44.74%
ROE
-39.13%
Face Value
—
EPS
$-3.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
152
Beta
-0.15
Debt / Equity
16.64
Current Ratio
12.53
Quick Ratio
12.53
Forward P/E
-3.92
Price / Sales
20.33
Enterprise Value
$241.23 M
EV / EBITDA
-1.59
EV / Revenue
9.49
Rating
Strong Buy
Target Price
$20.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 2. | Seres Therapeutics, Inc. | $8.94 | 15.05 | $85.7 M | — | -79.05% | 19.64% | $29.98 / $6.53 | $4.63 |
| 3. | Lexicon Pharmaceuticals, Inc. | $1.84 | — | $764.74 M | — | -29.8% | -39.72% | $1.95 / $0.49 | $0.3 |
| 4. | Imunon, Inc. | $3.1 | — | $12.36 M | — | -191.16% | -2.56% | $41.22 / $2.52 | $2.42 |
| 5. | Agenus Inc. | $4.42 | 1,529.26 | $175.86 M | — | 21.26% | -0.04% | $7.34 / $1.6 | $-7.68 |
| 6. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 7. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.3 M | 1.61 M | 1.95 M | 20.56 M | 37.4 M |
| Operating Profit | -42.21 M | -47.05 M | -46.85 M | -21.79 M | -5.87 M |
| Net Profit | -39.16 M | -44.13 M | -43.1 M | -17.35 M | 1.13 M |
| EPS in Rs | -1.02 | -1.15 | -1.13 | -0.45 | 0.03 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 25.42 M | 210.78 M | 129.01 M | 0 M |
| Operating Profit | -157.9 M | 47.01 M | -3.16 M | -97.25 M |
| Net Profit | -143.75 M | 65.63 M | -6.68 M | -94.62 M |
| EPS in Rs | -3.75 | 1.71 | -0.17 | -2.47 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 377.38 M | 526.32 M | 469.19 M | 252.06 M |
| Total Liabilities | 71.25 M | 97.64 M | 226.83 M | 39.5 M |
| Equity | 306.13 M | 428.68 M | 242.36 M | 212.55 M |
| Current Assets | 306.25 M | 440.04 M | 369.77 M | 209.88 M |
| Current Liabilities | 24.45 M | 39.48 M | 158.8 M | 21.97 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -128.51 M | -41.56 M | 139.8 M | -93.79 M |
| Investing CF | 116.81 M | -27.8 M | -138.4 M | -148.65 M |
| Financing CF | 0.89 M | 102.96 M | 21.04 M | 0.48 M |
| Free CF | -129.55 M | -44.72 M | 134.19 M | -96.67 M |
| Capex | -1.04 M | -3.16 M | -5.61 M | -2.89 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 63.38% | — | — | — |
| Earnings Growth % | 1081.69% | 92.93% | — | — |
| Profit Margin % | 31.13% | -5.18% | — | — |
| Operating Margin % | 22.3% | -2.45% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 24.09% | -0.25% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.